NVS: 6-K company filing

6-K 1 f6k_090126.htm FORM 6-K Nguyen, Nhat Migrator Account 0x01010021DCF4D64322AB4295494FCB7124D574 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 or 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 Report on Form 6-K dated September 1, 2026 (Commission File No. 1-15024) ____________________ Novartis AG (Name of Registrant) Lichtstrasse 35 4056 Basel Switzerland (Address of Principal Executive Offices) ____________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F: ☒ Form 40-F: ☐ Novartis International AG CH-4002 Basel Switzerland www.novartis.com x.com/novartisnews PRESS RELEASE Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials Ad hoc announcement pursuant to Art. 53 LR · REMODEL-1/-2 trials met their primary endpoint, significantly reducing annualized relapse rate (ARR) vs teriflunomide in people living with relapsing multiple sclerosis (RMS) 1 · Trials showed superiority of remibrutinib vs. teriflunomide on all key secondary endpoints within each trial, including reduction of MRI lesions 1 · A clinically meaningful delay in disability progression was achieved, including a positive trend in 3mCDP and nominally significant 6mCDP in preplanned combined analysis of REMODEL-1/-2 1 · Remibrutinib demonstrated a favorable safety profile with no liver safety signal, consistent with remibrutinib in chronic spontaneous urticaria (CSU) 1 · Novartis to present late-breaking data at MSToronto2026 and plans to submit to health authorities globally Basel, September 1, 2026